FLT3 and acute myeloid leukemia: Midostaurin, a multi-targeted kinase inhibitor, showed improved overall survival in combination with standard chemotherapy in a phase III trial (RATIFY) conducted in newly diagnosed FLT3-mutated AML patients [20].